What amount sold does Accele BioPharma, Inc. report in Form D filings?

The latest linked filings report $2.6M sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Accele BioPharma, Inc.'s most recent SEC filing?

Accele BioPharma, Inc.'s most recent Form D filing was on 2012-09-04.

How many investors does Accele BioPharma, Inc. have?

The most recent Form D filing lists 6 investor(s).

What type of securities does Accele BioPharma, Inc. offer?

Accele BioPharma, Inc.'s SEC Form D filings indicate equity offerings.

Accele BioPharma, Inc.

CIK: 0001556986·Other Health Care·OKLAHOMA CITY, OK·Corporation·Founded 2012

Reported Sold

$2,600,639

Total Filings

Identified Offerings

Last Filed

Sep 4, 2012

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Other Health Care industry

SEC EDGAR

Offering filing timeline

Sep 4, 2012Form D — New notice

Reported sold: $2,600,639 · Target: $2,600,639

Rule 506·6 investors

Fundraising Profile

Exemptions

Rule 506

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 1 identified offering

$2,600,639

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Filing History

Date	Type	Offering target	Reported sold	Investors
Sep 4, 2012	New	$2,600,639	$2,600,639	6

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

PulsePoint Lake Norman ASC, LLC

Other Health Care

Offering target: $1,760,000

Filed Nov 4, 2026